Evommune, Inc. EVMN
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Evommune, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for immune-mediated chronic inflammatory diseases. Founded in 2020 and headquartered in Palo Alto, California, Evommune aims to create innovative treatments that address major unmet medical needs in cond…
SectorHealthcare
ExchangeNYSE
IndustryBiotechnology
CountryUnited States
Employees48
TickerEVMN
Statistics
Market Cap$744.1M
Revenue (TTM)$13.0M
Net Income-$68.9M
Net Margin-529.8%
EPS$-11.22
P/E-1.87
P/S73.80
P/B2.42
EV/EBITDA-6.04
ROE-45.0%
Dividend Yield—
Price$20.66
Data: Twelve Data · Revenue = mcap / P/S